Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs
- PMID: 19148942
- DOI: 10.1002/hep.22673
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs
Abstract
Six major hepatitis C virus (HCV) genotypes and numerous subtypes have been described, and recently a seventh major genotype was discovered. Genotypes show significant molecular and clinical differences, such as differential response to combination therapy with interferon-alpha and ribavirin. Recently, HCV research has been accelerated by cell culture systems based on the unique growth capacity of strain JFH1 (genotype 2a). By development of JFH1-based intergenotypic recombinants containing Core, envelope protein 1 and 2 (E1, E2), p7, and nonstructural protein 2 (NS2) of genotype 6a and 7a strains, as well as subtype 1b and 2b strains, we have completed a panel of culture systems for all major HCV genotypes. Efficient growth in Huh7.5 cells depended on adaptive mutations for HK6a/JFH1 (6a/2a, in E1 and E2) and J4/JFH1 (1b/2a, in NS2 and NS3); viability of J8/JFH1 (2b/2a) and QC69/JFH1 (7a/2a) did not require adaptation. To facilitate comparative studies, we generated virus stocks of genotype 1-7 recombinants with infectivity titers of 10(3.7) to 10(5.2) 50% tissue culture infectious dose/mL and HCV RNA titers of 10(7.0) to 10(7.9) IU/mL. Huh7.5 cultures infected with genotype 1-6 viruses had similar spread kinetics, intracellular Core, NS5A, and lipid amounts, and colocalization of Core and NS5A with lipids. Treatment with interferon-alpha2b but not ribavirin or amantadine showed a significant antiviral effect. Infection with all genotypes could be blocked by specific antibodies against the putative coreceptors CD81 and scavenger receptor class B type I in a dose-dependent manner. Finally, neutralizing antibodies in selected chronic phase HCV sera had differential effects against genotype 1-7 viruses.
Conclusion: We completed and characterized a panel of JFH1-based cell culture systems of all seven major HCV genotypes and important subtypes and used these viruses in comparative studies of antivirals, HCV receptor interaction, and neutralizing antibodies.
Similar articles
-
Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.Gastroenterology. 2007 Nov;133(5):1614-26. doi: 10.1053/j.gastro.2007.08.005. Epub 2007 Aug 3. Gastroenterology. 2007. PMID: 17983807
-
Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.J Infect Dis. 2008 Dec 15;198(12):1756-65. doi: 10.1086/593021. J Infect Dis. 2008. PMID: 19032070
-
Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002. doi: 10.1073/pnas.0711044105. Epub 2008 Jan 14. Proc Natl Acad Sci U S A. 2008. PMID: 18195353 Free PMC article.
-
Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.Adv Virus Res. 2008;71:51-133. doi: 10.1016/S0065-3527(08)00002-X. Adv Virus Res. 2008. PMID: 18585527 Review.
-
Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.Antiviral Res. 2018 Oct;158:264-287. doi: 10.1016/j.antiviral.2018.07.014. Epub 2018 Jul 27. Antiviral Res. 2018. PMID: 30059723 Review.
Cited by
-
New hepatitis C virus drug discovery strategies and model systems.Expert Opin Drug Discov. 2012 Sep;7(9):849-59. doi: 10.1517/17460441.2012.711312. Epub 2012 Aug 4. Expert Opin Drug Discov. 2012. PMID: 22861052 Free PMC article. Review.
-
Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.J Infect Dis. 2010 Sep 15;202(6):862-6. doi: 10.1086/655902. J Infect Dis. 2010. PMID: 20677942 Free PMC article. Clinical Trial.
-
Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design.PLoS Pathog. 2019 May 17;15(5):e1007772. doi: 10.1371/journal.ppat.1007772. eCollection 2019 May. PLoS Pathog. 2019. PMID: 31100098 Free PMC article.
-
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.Gastroenterology. 2022 Feb;162(2):562-574. doi: 10.1053/j.gastro.2021.10.005. Epub 2021 Oct 13. Gastroenterology. 2022. PMID: 34655573 Free PMC article.
-
Griffithsin has antiviral activity against hepatitis C virus.Antimicrob Agents Chemother. 2011 Nov;55(11):5159-67. doi: 10.1128/AAC.00633-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896910 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials